ASCO: Biologics Work Synergistically Against Metastatic Breast Cancer if Trastuzumab Regimens Fail
June 3, 2008
By Crystal Phend, Staff Writer, MedPage Today
CHICAGO — Combining targeted biologic therapies after progression of metastatic HER2-positive breast cancer may improve response despite prior treatment with multiple trastuzumab (Herceptin) regimens.Addition of the tyrosine kinase inhibitor lapatinib (Tykerb) to the monoclonal antibody trastuzumab reduced risk of disease progression 27% compared with lapatinib alone, reported Joyce O’Shaughnessy, M.D., of the Baylor-Sammons Cancer Center in Dallas, and colleagues here at the American Society of Clinical Oncology meeting.
Karmanos Cancer Institute Researchers Show Phase I Immunotherapy with Armed T Cells Improve Overall Survival of Metastatic Breas
June 2, 2008
CHICAGO — Researchers at the Barbara Ann Karmanos
Cancer Institute in Detroit today presented findings that show immunotherapy with armed targeted T cells may improve the overall survival of women with metastatic breast cancer.
New Hope for a Failed Cancer Drug
June 2, 2008
By Catherine Arnst, Business Week
AstraZeneca’s Iressa took an FDA hit in 2005 as a lung cancer treatment, but a recent study showed its potential in breast cancer patients.
There may be a second life for Iressa, AstraZeneca’s once-promising cancer drug that came to symbolize the hype surrounding a new generation of targeted cancer treatments. Iressa won U.S. Food & Drug Administration approval for lung cancer in 2003 amid much fanfare, labeled by some as a “miracle drug.” Two years later, AstraZeneca (AZN) was forced to stop marketing the drug in the U.S. because it failed in a subsequent clinical trial to help patients live longer.
Doctors continued to experiment with the drug, however, which is how researchers at M.D. Anderson Cancer Center in Houston made the surprising discovery that Iressa can significantly delay the spread of breast cancer when given along with standard hormone therapy.
Second Phase III Study of Avastin Plus Chemotherapy Shows Improved Progression-Free Survival in Women With Advanced HER2-Negativ
June 1, 2008
By Genentech Press Release
Chicago – Genentech, Inc. (NYSE: DNA) today announced that Avastin® (bevacizumab), in combination with docetaxel chemotherapy, significantly increased the time women with metastatic breast cancer receiving first-line therapy lived without their disease advancing, as defined by the primary endpoint of progression-free survival (PFS).